...
search icon
tlsa-img

Tiziana Life Sciences Ltd, Common Stock

TLSA

NAQ

$0.8001

+$0.01

(1.27%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$93.49M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
178.72K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.16
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.46 L
$1.91 H
$0.8001

About Tiziana Life Sciences Ltd, Common Stock

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTLSASectorS&P500
1-Week Return-11.12%3.03%5.82%
1-Month Return-49.04%-4.41%-5.2%
3-Month Return10.36%-1.04%-8.35%
6-Month Return-13.88%-10.47%-8.66%
1-Year Return60.05%-0.06%5.81%
3-Year Return-15.77%-0.07%21.87%
5-Year Return-39.78%42.65%88.01%
10-Year Return-51.68%87.77%155.47%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue250.04K89.76K141.00K51.00K-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":35.9,"profit":true},{"date":"2021-12-31","value":56.39,"profit":true},{"date":"2022-12-31","value":20.4,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit(250.04K)(89.76K)(141.00K)(51.00K)-[{"date":"2019-12-31","value":-25004400,"profit":false},{"date":"2020-12-31","value":-8976400,"profit":false},{"date":"2021-12-31","value":-14100000,"profit":false},{"date":"2022-12-31","value":-5100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses7.77M30.04M27.37M14.59M17.98M[{"date":"2019-12-31","value":25.88,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.13,"profit":true},{"date":"2022-12-31","value":48.56,"profit":true},{"date":"2023-12-31","value":59.87,"profit":true}]
Operating Income(7.77M)(28.03M)(27.37M)(14.59M)(17.98M)[{"date":"2019-12-31","value":-777300000,"profit":false},{"date":"2020-12-31","value":-2802600000,"profit":false},{"date":"2021-12-31","value":-2737400000,"profit":false},{"date":"2022-12-31","value":-1458600000,"profit":false},{"date":"2023-12-31","value":-1798400000,"profit":false}]
Total Non-Operating Income/Expense(145.00K)(624.00K)541.00K(818.00K)1.89M[{"date":"2019-12-31","value":-7.69,"profit":false},{"date":"2020-12-31","value":-33.09,"profit":false},{"date":"2021-12-31","value":28.69,"profit":true},{"date":"2022-12-31","value":-43.37,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(7.85M)(28.34M)(26.66M)(15.40M)(17.24M)[{"date":"2019-12-31","value":-784600000,"profit":false},{"date":"2020-12-31","value":-2833800000,"profit":false},{"date":"2021-12-31","value":-2665700000,"profit":false},{"date":"2022-12-31","value":-1539700000,"profit":false},{"date":"2023-12-31","value":-1724200000,"profit":false}]
Income Taxes(540.00K)(2.21M)(3.24M)811.00K449.00K[{"date":"2019-12-31","value":-66.58,"profit":false},{"date":"2020-12-31","value":-272.13,"profit":false},{"date":"2021-12-31","value":-399.51,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.36,"profit":true}]
Income After Taxes(7.31M)(26.13M)(23.42M)(16.21M)(17.69M)[{"date":"2019-12-31","value":-730600000,"profit":false},{"date":"2020-12-31","value":-2613100000,"profit":false},{"date":"2021-12-31","value":-2341700000,"profit":false},{"date":"2022-12-31","value":-1620800000,"profit":false},{"date":"2023-12-31","value":-1769100000,"profit":false}]
Income From Continuous Operations(7.31M)(26.13M)(23.42M)(15.40M)(17.69M)[{"date":"2019-12-31","value":-730600000,"profit":false},{"date":"2020-12-31","value":-2613100000,"profit":false},{"date":"2021-12-31","value":-2341700000,"profit":false},{"date":"2022-12-31","value":-1539700000,"profit":false},{"date":"2023-12-31","value":-1769100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(7.31M)(26.13M)(23.42M)(15.40M)(17.69M)[{"date":"2019-12-31","value":-730600000,"profit":false},{"date":"2020-12-31","value":-2613100000,"profit":false},{"date":"2021-12-31","value":-2341700000,"profit":false},{"date":"2022-12-31","value":-1539700000,"profit":false},{"date":"2023-12-31","value":-1769100000,"profit":false}]
EPS (Diluted)(0.31)(0.18)---[{"date":"2019-12-31","value":-30.99,"profit":false},{"date":"2020-12-31","value":-17.66,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TLSA
Cash Ratio 0.18
Current Ratio 1.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TLSA
ROA (LTM) -69.58%
ROE (LTM) -181.23%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TLSA
Debt Ratio Lower is generally better. Negative is bad. 0.55
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.45

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TLSA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 49.77
EV/R 0.00
EV/Ebitda NM

FAQs

What is Tiziana Life Sciences Ltd share price today?

Tiziana Life Sciences Ltd (TLSA) share price today is $0.8001

Can Indians buy Tiziana Life Sciences Ltd shares?

Yes, Indians can buy shares of Tiziana Life Sciences Ltd (TLSA) on Vested. To buy Tiziana Life Sciences Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TLSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Tiziana Life Sciences Ltd be purchased?

Yes, you can purchase fractional shares of Tiziana Life Sciences Ltd (TLSA) via the Vested app. You can start investing in Tiziana Life Sciences Ltd (TLSA) with a minimum investment of $1.

How to invest in Tiziana Life Sciences Ltd shares from India?

You can invest in shares of Tiziana Life Sciences Ltd (TLSA) via Vested in three simple steps:

  • Click on Sign Up or Invest in TLSA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Tiziana Life Sciences Ltd shares
What is Tiziana Life Sciences Ltd 52-week high and low stock price?

The 52-week high price of Tiziana Life Sciences Ltd (TLSA) is $1.91. The 52-week low price of Tiziana Life Sciences Ltd (TLSA) is $0.46.

What is Tiziana Life Sciences Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Tiziana Life Sciences Ltd (TLSA) is 49.77

What is the Market Cap of Tiziana Life Sciences Ltd?

The market capitalization of Tiziana Life Sciences Ltd (TLSA) is $93.49M

What is Tiziana Life Sciences Ltd’s stock symbol?

The stock symbol (or ticker) of Tiziana Life Sciences Ltd is TLSA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top